Ms. Rachelle MacSweeney reports

PIVOTAL THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS

Pivotal Therapeutics Inc. has released its operational highlights and financial results for the six months ended June 30, 2015. (All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.)

Operational highlights for second quarter 2015:

• Received notice of allowance for U.S. patent application No. 13/584,428 related to a kit for the dietary management of cardiovascular patients with cardiovascular disease, who are deficient in blood EPA and DHA levels, that includes Vascazen and an omega-3 fatty acid diagnostic assay;
• Executed a memorandum of understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products in Korea;
• Received Health Canada approval to expand the indication of Omazen to include products with claims to maintain and support cardiovascular health and normal triglyceride levels;
• Pivotal and Rachelle MacSweeney, co-founder, president and chief operating officer, featured on CEO Clips on CBC's The Documentary Channel;
• Enrolled first patient in Pivotal's Pomega phase IIa clinical trial with PVT-100.

The previously announced private equity financing is being received far better than anticipated and to facilitate this the company has extended this offer. The company is currently in negotiations with new investors.

Financial results

For the six months ended June 30, 2015, the company reported an increase in sales of 112 per cent to $268,176 ($126,323: 2014), a decrease in operating expenses of 55 per cent to $1,603,162 ($3,539,190: 2014) and a decrease of 30 per cent in net loss to $2,646,253 ($3,786,445: 2014).

The audited consolidated financial statements, accompanying notes thereto, and management's discussion and analysis for the six months ended June 30, 2015, will be accessible on SEDAR, the Canadian Securities Exchange website under the symbol PVO and the OTCQX website under the symbol PVTTF.

About Vascazen

Vascazen is currently available in the United States as a prescription-only medical food specifically formulated for the dietary management of an omega-3 deficiency in cardiovascular patients. Vascazen is a more-than-90-per-cent-pure omega-3 with a proprietary 6 to 1 EPA to DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

Vascazen has been clinically shown to correct an omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48-per-cent reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile.

About Omazen

Omazen is Pivotal's second commercial product to market and is available for sale and distribution for the professional over-the-counter market in Canada. Omazen contains greater-than-90-per-cent-pure, pharmaceutical-grade omega-3 with a unique ratio of EPA to DHA for the maintenance of good health. Omazen, like all of Pivotal's products, is backed by clinical data and scientific support providing a superior alternative to what is currently available on the market.

About BeneFishial

BeneFishial was created as the cornerstone of the company's new nutraceutical product line, which will include prenatal-, children-, heart- and animal-health-oriented products. BeneFishial is designed to be sold as a nutraceutical in the OTC direct-to-retail or direct-to-consumer markets in both the United States and in Canada. BeneFishial contains the highest content of omega-3 fatty acids of any other OTC product on the market. It is specifically formulated to give the highest-purity, highest-anti-inflammatory properties and the best therapeutic effect for a healthy body and mind. It contains the optimal purity, ratio and dose of omega-3 and is a simple solution to a number of health risk factors.

We seek Safe Harbor.